SLSBio(Specialty Lab Solution Bio) Co., Ltd: debt-to-equity, ROE and more
KOSDAQ, Legal name SLSBio(Specialty Lab Solution Bio) Co., Ltd
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 47.1%
- Equity ratio
- 68.0%
- ROE
- -64.2%
- Op. margin
- -103.0%
- Rev. growth
- -52.4%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 1 straight year.
- Total equity is below paid-in capital: partial impairment (자본잠식), rate 0.5%.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | n/a | n/a |
| 2024 | n/a | n/a |
| 2023 | n/a | 26.8% |
No cash dividend in the latest fiscal year, or no value reported.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 182.1% | 35.4% | 1.6% | 5.2% | n/a |
| FY2022 separate | 75.3% | 57.1% | 42.1% | 22.5% | 30.4% |
| FY2023 separate | 32.5% | 75.5% | 10.6% | 11.4% | -16.1% |
| FY2024 separate | 30.7% | 76.5% | 2.7% | 3.4% | -7.2% |
| FY2025 separate | 47.1% | 68.0% | -64.2% | -103.0% | -52.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩8.2B | ₩10.8B | ₩9.0B | ₩8.4B | ₩4.0B |
| Operating profit | ₩426.2M | ₩2.4B | ₩1.0B | ₩287.6M | -₩4.1B |
| Pre-tax income | ₩258.9M | ₩2.2B | ₩1.1B | ₩354.1M | -₩5.4B |
| Net income | ₩57.9M | ₩2.8B | ₩1.4B | ₩335.6M | -₩4.9B |
| Total assets | ₩10.5B | ₩11.8B | ₩17.8B | ₩16.4B | ₩11.2B |
| Total liabilities | ₩6.8B | ₩5.0B | ₩4.4B | ₩3.8B | ₩3.6B |
| Total equity | ₩3.7B | ₩6.7B | ₩13.5B | ₩12.5B | ₩7.6B |
| Paid-in capital | ₩3.4B | ₩3.4B | ₩3.8B | ₩7.7B | ₩7.7B |
| Debt/equity (source value) | 182.1% | 75.3% | 32.5% | 30.7% | 47.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2007-01-17
- Listed
- 23/10/20
- Employees
- 63
- Auditor
- 정진세림회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101113602524
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 에스엘에스바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.